Shaping a new paradigm in drug delivery to advance the future of genetic medicine

Boston, MA, April 16, 2025 – Cytodigm, a leader in advanced nanoparticle delivery systems, in collaboration with Harvard Medical School and Brown University, proudly announces the publication of groundbreaking research in the Feb 2025 issue of Science Advances. The study, titled “Modulation of Blood-Tumor Barrier Transcriptional Programs Improves Intratumoral Drug Delivery and Potentiates Chemotherapy in GBM,” showcases the innovative potential of Cytodigm’s proprietary nanoparticle, PPRX-1701, in overcoming delivery challenges associated with glioblastoma multiforme (GBM).

On June 4, 2025, in Boston, Dr. Bin Wu, Founder and CEO of Cytodigm, will present “Exploring Treatment Engineering Approaches to Overcome Off-Target Toxicity” at the 4th In Vivo Cell Engineering & Gene Editing Summit.

On May 16, 2025, in New Orleans, LA, Dr. Bin Wu, Founder and CEO of Cytodigm, will present “Leveraging Novel PEG-free Lipid Nanoparticles for Tissue and Cell Targeting” at the 28th Annual Meetings of American Society of Cell & Gene Therapy.

In Boston, on June 25, 2025, Dr. Bin Wu, Cytodigm’s Founder and CEO, will present “Redefining Nanoparticle Delivery: PEG-Free LNP Formulation for Targeted & Extrahepatic Applications” at the 4th Annual Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit.”

Dr. Bin Wu, our Founder and CEO, recently delivered a compelling presentation at the 3rd LNP Immunogenicity and Toxicity Summit in Boston, showcasing Cytodigm’s innovative Cytofinity™ LNP technology.

In Boston, on December 11, 2024, Dr. Bin Wu, Cytodigm’s Founder and CEO, will present “Case Study: Building Next-Generation LNPs with Gangliosides Instead of PEG

Natick, MA, February 6, 2024  – Cytodigm, a biopharmaceutical company developing innovative delivery systems for nucleic acid therapeutics, announced…

Boston, MA, December 11, 2023 – Victoria Trantow, R&D Scientist at Cytodigm, presented a poster titled “CytofinityTM PEG-free…